How many 8-K filings has Sigyn Therapeutics, Inc. filed?

Sigyn Therapeutics, Inc. (SIGY) has 12 8-K (Current Event Report) filings on record, spanning Jan 2024 to Aug 2025.

What is a 8-K filing?

A 8-K is an SEC filing known as "Current Event Report." Filed to announce significant events or material changes such as acquisitions, executive departures, earnings announcements, or bankruptcy filings.

Where can I read Sigyn Therapeutics, Inc. 8-K filings in plain English?

ReadTheFiling provides AI-powered plain-English summaries of all Sigyn Therapeutics, Inc. 8-K filings, including risk assessment, sentiment analysis, and key financial figures.

Sigyn Therapeutics, Inc. (SIGY) — 8-K Filings

All 8-K filings from Sigyn Therapeutics, Inc.. Browse 12 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (12)

Sigyn Therapeutics Files 8-K: Material Agreement, Equity Sales, Officer Changes — Aug 15, 2025 Risk: medium
Sigyn Therapeutics, Inc. announced on August 14, 2025, that it entered into a material definitive agreement. The company also reported on unregistered sales of
Sigyn Therapeutics Announces Board Changes and Officer Appointments — Mar 7, 2025 Risk: medium
Sigyn Therapeutics, Inc. announced on February 26, 2025, a change in its board of directors, with the election of new directors and the appointment of certain o
Sigyn Therapeutics Announces Board and Executive Changes — Jan 16, 2025 Risk: medium
Sigyn Therapeutics, Inc. announced on January 11, 2025, changes in its board of directors and executive compensation. The filing details the departure of certai
Sigyn Therapeutics Files 8-K with Corporate Updates — Jan 6, 2025 Risk: low
Sigyn Therapeutics, Inc. filed an 8-K on January 6, 2025, reporting events as of December 30, 2024. The filing includes amendments to its articles of incorporat
Sigyn Therapeutics Sells Shares for $100 — Oct 7, 2024 Risk: low
On October 4, 2024, Sigyn Therapeutics, Inc. reported the unregistered sale of 1,000,000 shares of its common stock at an exercise price of $0.0001 per share. T
Sigyn Therapeutics Announces $5M Stock Repurchase Program — Jun 6, 2024 Risk: medium
Sigyn Therapeutics, Inc. announced on June 6, 2024, that its Board of Directors approved a stock repurchase program. The company may repurchase up to $5.0 milli
Sigyn Therapeutics Changes Principal Executive Offices — May 15, 2024 Risk: low
Sigyn Therapeutics, Inc. filed an 8-K on May 15, 2024, reporting an event that occurred on May 9, 2024. The filing indicates a change in the company's principal
Sigyn Therapeutics Enters Material Definitive Agreement — Apr 16, 2024 Risk: medium
On April 16, 2024, Sigyn Therapeutics, Inc. reported an entry into a material definitive agreement. The earliest event reported in relation to this agreement wa
Sigyn Therapeutics Updates Principal Office, Phone Number — Jan 31, 2024
Sigyn Therapeutics, Inc. filed an 8-K on January 31, 2024, to update its principal executive offices from 9190 W Olympic Blvd #263, Beverly Hills, CA 90212 to 2
Sigyn Therapeutics Relocates HQ to Beverly Hills — Jan 30, 2024
On January 30, 2024, Sigyn Therapeutics, Inc. filed an 8-K to report a change in its principal executive offices from 2468 Historic Decatur Road, Suite 140, San
Sigyn Therapeutics Files 8-K on Material Agreement; Details Undisclosed — Jan 11, 2024
Sigyn Therapeutics, Inc. filed an 8-K on January 11, 2024, reporting an "Entry into a Material Definitive Agreement" and "Other Events" that occurred on January
Sigyn Therapeutics Relocates HQ to Beverly Hills — Jan 8, 2024
Sigyn Therapeutics, Inc. filed an 8-K on January 8, 2024, to update its principal executive offices. The company's new business address is 9190 W Olympic Blvd #

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX